Evidence map›Paper›PMID 34196224›Full record

ArticleNanomedicine (London, England)2021

Micro- and nanotechnological delivery platforms for treatment of dysbiosis-related inflammatory bowel disease.

Dingpei Long, Didier Merlin

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dingpei LongInstitute for Biomedical Sciences, Center for Inflammation, Immunity & Infection, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, USA.ORCID 0000-0002-2907-6901
Didier MerlinInstitute for Biomedical Sciences, Center for Inflammation, Immunity & Infection, Digestive Disease Research Group, Georgia State University, Atlanta, GA 30302, USA.

Funding

Fecal exosomes as a source of miRNA biomarkers for diagnosing the degree of colitis and as a drug delivery system to reduce colitisR01DK116306 · NIDDK · GEORGIA STATE UNIVERSITY · PI DENNING, TIMOTHY L, GEWIRTZ, ANDREW T · 2017 to 2020
$1.8M
Novel Therapeutic Approaches For Treatment of Intestinal InflammationR01DK107739 · NIDDK · GEORGIA STATE UNIVERSITY · PI DENNING, TIMOTHY L, MERLIN, DIDIER · 2017 to 2020
$1.4M
Small intestinal PepT1 expression plays a critical role in maintaining intestinal homeostasis and in shaping the gut microbiotaI01BX002526 · VA · VETERANS HEALTH ADMINISTRATION · PI MERLIN, DIDIER · 2014 to 2024
–
BLR&D Research Career Scientist Award ApplicationIK6BX004476 · VA · VETERANS HEALTH ADMINISTRATION · PI MERLIN, DIDIER · 2019 to 2025
–
BLRD VA I01 BX002526BLRD VA IK6 BX004476NIDDK NIH HHS R01 DK107739NIDDK NIH HHS R01 DK116306NIDDK NIH HHS RO1-DK-107739, RO1-DK-116306Research Fellowship Award from the Crohn's and Colitis Foundation of America #689659U.S. Department of Veterans Affairs BX002526, BX004476
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ColitisInflammatory Bowel DiseasesDysbiosisHumansfecal microbiota transplantationgut microbiotainflammatory bowel diseaseinorganic nanoparticlesintestinal dysbiosislipid nanoparticlesmicrobiome metabolitesnanotechnology

Identifiers

PMID34196224
PMCPMC8336662

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.